| 1 |
programmed death-1
(5787 times)
|
Neoplasms
(1930 times)
|
PD-L1 (1927 times)
CTLA-4 (682 times)
NSCLC (602 times)
|
1997 Activation-induced expression of human programmed death-1 gene in T-lymphocytes.
|
| 2 |
PDCD-1
(7 times)
|
Neoplasms
(2 times)
|
MSI (2 times)
ACT (1 time)
BC (1 time)
|
2015 Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.
|
| 3 |
programmed death molecule-1
(7 times)
|
Allergy and Immunology
(2 times)
|
CTLA-4 (2 times)
RA (2 times)
aGVHD (1 time)
|
2009 Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
|
| 4 |
PD-L1 or programmed cell death-1
(5 times)
|
Neoplasms
(2 times)
|
PD-L1 (4 times)
ADC (1 time)
APACHE (1 time)
|
2017 PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1alpha.
|
| 5 |
anti-PD-1 immunotherapy
(3 times)
|
Neoplasms
(3 times)
|
RFS (2 times)
BRAFi (1 time)
ICIs (1 time)
|
2021 Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
|
| 6 |
death-protein 1
(3 times)
|
Nuclear Medicine
(1 time)
|
PD-L1 (2 times)
Ab (1 time)
CTL (1 time)
|
2019 A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
|
| 7 |
PD-1hi
(3 times)
|
Microbiological Phenomena
(1 time)
|
EC (1 time)
FACS (1 time)
FV (1 time)
|
2018 Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
|
| 8 |
Programmed death axis 1
(3 times)
|
Medicine
(2 times)
|
T1D (3 times)
CD (1 time)
PBMC (1 time)
|
2016 PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
|
| 9 |
anti-PD-1 antibodies
(2 times)
|
Liver Neoplasms
(1 time)
|
LEN (2 times)
DFS (1 time)
HCC (1 time)
|
2021 Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
|
| 10 |
anti-PD-1 antibody monotherapy
(2 times)
|
Neoplasms
(1 time)
|
ORR (2 times)
OS (2 times)
PFS (2 times)
|
2022 Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
|
| 11 |
anti-PDCD1
(2 times)
|
Neoplasms
(1 time)
|
B2M (1 time)
FSP (1 time)
MMR (1 time)
|
2018 High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.
|
| 12 |
anti-program cell death -1
(2 times)
|
Neoplasms
(1 time)
|
aNSCLC (1 time)
BMI (1 time)
BOR (1 time)
|
2020 PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.
|
| 13 |
PDCD1, CD279
(2 times)
|
Pathology
(1 time)
|
ALDH1 (1 time)
AML (1 time)
|
2017 Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
|
| 14 |
programmed cell death-1 protein receptor
(2 times)
|
Neoplasms
(2 times)
|
CI (1 time)
ctDNA (1 time)
ctDNA TMB (1 time)
|
2016 Biomarkers for PD-1/PD-L1 Blockade Therapy inNon-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
|
| 15 |
programmed death 1 positive
(2 times)
|
Medicine
(1 time)
|
ICOS (2 times)
AUC (1 time)
BCL6 (1 time)
|
2016 [Detection of peripheral follicular helper T cells in rheumatoid arthritis].
|
| 16 |
protein death-1
(2 times)
|
Immune System Diseases
(1 time)
|
CTLA-4 (1 time)
ICB (1 time)
|
2016 PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients.
|
| 17 |
Anti(alpha)-programmed cell death-1
(1 time)
|
Immunotherapy
(1 time)
|
DLN (1 time)
IL (1 time)
M-MDSC (1 time)
|
2020 Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
|
| 18 |
anti-PD-1 was used to activate or block the programmed death
(1 time)
|
Medicine
(1 time)
|
CD28 (1 time)
ELISA (1 time)
IFN-gamma (1 time)
|
2019 PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
|
| 19 |
anti-PD-L1/anti- programmed cell death 1
(1 time)
|
Neoplasms
(1 time)
|
DFS (1 time)
LNMs (1 time)
PD-L1 (1 time)
|
2018 Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
|
| 20 |
anti-programmed death-1 antibodies
(1 time)
|
Chemistry
(1 time)
|
CA (1 time)
HSA (1 time)
|
2021 Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation.
|
| 21 |
CAMPANELLIProgrammed Death 1
(1 time)
|
Dental Pulp Diseases
(1 time)
|
PD-L1 (2 times)
|
2020 CAMPANELLIProgrammed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis.
|
| 22 |
death protein 1 receptor
(1 time)
|
|
cSCC (1 time)
|
2020 Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab.
|
| 23 |
particular, inhibition of the antiprogrammed death-1
(1 time)
|
Medicine
(1 time)
|
CI (1 time)
CT (1 time)
EORTC (1 time)
|
2021 A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
|
| 24 |
particularly antiprogrammed death 1
(1 time)
|
Neoplasms
(1 time)
|
CPI (1 time)
|
2019 Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
|
| 25 |
patient was initiated on antiprogrammed-death receptor 1
(1 time)
|
Medicine
(1 time)
|
SRS (1 time)
VS (1 time)
|
2021 Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment.
|
| 26 |
patients treated with antiprogrammed death receptor-1
(1 time)
|
Immunotherapy
(1 time)
|
LDH (1 time)
MGR (1 time)
OS (1 time)
|
2021 Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
|
| 27 |
PD-1 antagonist
(1 time)
|
General Surgery
(1 time)
|
NT (1 time)
pCR (1 time)
TVEC (1 time)
|
2022 Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.
|
| 28 |
PD-1 decoy
(1 time)
|
Immunity
(1 time)
|
PD-L1 (1 time)
|
2016 Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.
|
| 29 |
PD-1 expressed on T cells and its ligands
(1 time)
|
Neoplasms
(1 time)
|
MDSC (1 time)
TAM (1 time)
TIL (1 time)
|
2013 Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
|
| 30 |
PD-1 expression
(1 time)
|
Acquired Immunodeficiency Syndrome
(1 time)
|
ART (1 time)
|
2019 T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.
|
| 31 |
PD-1 pathway molecule
(1 time)
|
Allergy and Immunology
(1 time)
|
HIV (1 time)
SIV (1 time)
|
2022 A 16-color full spectrum flow cytometric analysis for comprehensive evaluation of T-cell reconstitution in SIV-infected rhesus macaques.
|
| 32 |
PD-1 receptor
(1 time)
|
Cells
(1 time)
|
NK (1 time)
NPC (1 time)
PD-L1 (1 time)
|
2021 Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
|
| 33 |
PD-1.1, PD-1.3, PD-1.5, PD-1.9
(1 time)
|
Clinical Medicine
(1 time)
|
CI (1 time)
CTLA-4 (1 time)
NSCLC (1 time)
|
2015 Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.
|
| 34 |
PD-1ECD
(1 time)
|
Natural Science Disciplines
(1 time)
|
---
|
2016 High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.
|
| 35 |
PD-1ex
(1 time)
|
Hematology
(1 time)
|
AML (1 time)
BiTE (1 time)
CiTE (1 time)
|
2018 Bifunctional PD-1 alphaCD3 alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
|
| 36 |
PD-L1 and its receptor
(1 time)
|
Hematology
(1 time)
|
PD-L1 (1 time)
|
2017 Clinical applications of PD-L1 bioassays for cancer immunotherapy.
|
| 37 |
PD-L1 mRNA levels were independent poor prognostic factors for OS
(1 time)
|
General Surgery
(1 time)
|
GC (1 time)
OS (1 time)
PB (1 time)
|
2018 Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
|
| 38 |
PD-L1 negative tumors
(1 time)
|
Internal Medicine
(1 time)
|
NENs (1 time)
PD (1 time)
TIL (1 time)
|
2020 Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
|
| 39 |
PDCD1LG2
(1 time)
|
Genetics
(1 time)
|
DEGs (1 time)
NSCLC (1 time)
PPI (1 time)
|
2023 Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.
|
| 40 |
pembrolizumab, an antiprogrammed cell death 1
(1 time)
|
Neoplasms
(1 time)
|
EGFR (1 time)
HNSCC (1 time)
|
2021 Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
|
| 41 |
Pembrolizumab: a novel antiprogrammed death 1
(1 time)
|
Pharmacy
(1 time)
|
---
|
2015 Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
|
| 42 |
percentages of GC TFH (CXCR5(high)PD-1(high)) and CXCR5(+)programmed cell death-1
(1 time)
|
Allergy and Immunology
(1 time)
|
EF (1 time)
GC (1 time)
TFH (1 time)
|
2016 Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication.
|
| 43 |
pools did not exceed 10% for all three assays
(1 time)
|
|
CV (1 time)
ELISA (1 time)
|
2022 High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood.
|
| 44 |
poor response to antiprogrammed cell death-1
(1 time)
|
Immunotherapy
(1 time)
|
DOR (1 time)
GEP (1 time)
MM (1 time)
|
2022 Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
|
| 45 |
population.Programmed death-1
(1 time)
|
Neoplasms
(1 time)
|
SBRT (1 time)
|
2023 Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
|
| 46 |
pPD-1A
(1 time)
|
Biotechnology
(1 time)
|
GFP (1 time)
|
2005 [Eukaryotic expression and functional characterization of PD-1 extracellular domain].
|
| 47 |
Priya Darshini-1
(1 time)
|
Nutritional Sciences
(1 time)
|
PR (1 time)
|
1986 Genetic regulation of carotene biosynthesis in selected tomato strains: aspects of beta-carotene biosynthesis and B gene specificity.
|
| 48 |
Program Death 1 receptor
(1 time)
|
Neoplasms
(1 time)
|
ALK (1 time)
EGFR (1 time)
NSCLC (1 time)
|
2017 Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.
|
| 49 |
programmed cell death-1 inhibitor
(1 time)
|
Hematologic Diseases
(1 time)
|
ORR (1 time)
|
2021 The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers.
|
| 50 |
programmed death 1 coinhibitory receptor
(1 time)
|
Biomedical Research
(1 time)
|
AML (1 time)
LAM (1 time)
TSC (1 time)
|
2018 TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
|
| 51 |
programmed death 1 on T cells
(1 time)
|
Neoplasms
(1 time)
|
AEs (1 time)
CTLA-4 (1 time)
HRQoL (1 time)
|
2017 Health-related quality of life results from the phase III CheckMate 067 study.
|
| 52 |
programmed death 1 pathway
(1 time)
|
Neoplasms
(1 time)
|
PD-L1 (1 time)
|
2015 Anti-PD-1 therapy in melanoma.
|
| 53 |
Programmed death cell receptor 1
(1 time)
|
Allergy and Immunology
(1 time)
|
APC (1 time)
|
2011 Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1.
|
| 54 |
programmed death-1 expression
(1 time)
|
Immune System Diseases
(1 time)
|
DEGs (1 time)
LaSig (1 time)
LUAD (1 time)
|
2022 Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma.
|
| 55 |
Programmed death-ligand 1 receptor
(1 time)
|
Medicine
(1 time)
|
AAV (1 time)
irAEs (1 time)
PD-L1 (1 time)
|
2022 Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.
|
| 56 |
Programmed necrosis factor 1
(1 time)
|
Allergy and Immunology
(1 time)
|
AP (1 time)
|
2021 PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis.
|
| 57 |
progressed on prior antiprogrammed death-1
(1 time)
|
Neoplasms
(1 time)
|
---
|
2022 Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.
|
| 58 |
project directorate-1
(1 time)
|
Animal Diseases
(1 time)
|
BV (1 time)
BW (1 time)
EP (1 time)
|
2020 Variance component analysis of growth and production traits in Vanaraja male line chickens using animal model.
|
| 59 |
protein 1:programmed death ligand 1
(1 time)
|
Molecular Biology
(1 time)
|
CTLA-4 (1 time)
|
2020 PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
|
A Search Service for Abbreviation / Long Form